Literature DB >> 2120209

The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system.

L Bajzár1, J C Fredenburgh, M Nesheim.   

Abstract

The effect of human activated protein C (APC) on fibrinolysis was studied in a cell-free system by continuously monitoring the thrombin-induced formation and subsequent tissue-type plasminogen activator-induced degradation of fibrin. In systems comprising dialyzed human plasma, APC shortens the time for lysis to occur in a concentration-dependent, saturable manner. Half-maximal activity occurs at an APC concentration of 10 nM. The effect is mediated by enhanced plasminogen activation and is dependent upon ionized calcium. The effect is lost when plasma adsorbed with barium citrate is utilized in place of unadsorbed plasma. The effect can be reconstituted, however, from components recovered from the barium citrate precipitate. Fractionation of the barium citrate adsorbable proteins with polyethylene glycol (PEG) provides two fractions, one of which is obtained by precipitation at 5% PEG, and the other of which is obtained from the 5% PEG supernatant by further precipitation at 40% PEG. The latter fraction contains Factor X and presumably the other vitamin K-dependent clotting factors. Both of these fractions together, but neither of them alone, fully reconstitute barium-adsorbed plasma, such that APC-enhanced fibrinolysis occurs as in non-adsorbed plasma. These fractions also are sufficient to provide for an APC effect in a system in which purified plasminogen and fibrinogen are used in place of barium citrate-adsorbed plasma. Thus, an effect of APC on tissue-type plasminogen activator-induced fibrinolysis exists which is Ca2(+)-dependent and requires two or more, as yet unidentified, components that can be precipitated from human plasma by barium citrate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120209

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

2.  Down regulation of prothrombinase by activated protein C during prothrombin activation.

Authors:  Paul Y Kim; Michael E Nesheim
Journal:  Thromb Haemost       Date:  2010-04-13       Impact factor: 5.249

Review 3.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

4.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

5.  Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

Authors:  P Gresele; S Momi; M Berrettini; G G Nenci; H P Schwarz; N Semeraro; M Colucci
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

6.  Expression of the peptide C4b-binding protein beta in the arthritic joint.

Authors:  O Sánchez-Pernaute; J Esparza-Gordillo; R Largo; E Calvo; M A Alvarez-Soria; M E Marcos; G Herrero-Beaumont; S R de Córdoba
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

7.  Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.

Authors:  E Furmaniak-Kazmierczak; T D Cooke; R Manuel; A Scudamore; H Hoogendorn; A R Giles; M Nesheim
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

9.  Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain.

Authors:  Paul Y Kim; Reginald Manuel; Michael E Nesheim
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

10.  Simultaneous activation of complement and coagulation by MBL-associated serine protease 2.

Authors:  Anders Krarup; Russell Wallis; Julia S Presanis; Péter Gál; Robert B Sim
Journal:  PLoS One       Date:  2007-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.